What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?

AbbVie presented phase 3 study data at the 2026 EADV Congress, showing Rinvoq (upadacitinib) demonstrated continued facial and body repigmentation in non-segmental vitiligo through week 76. The data also included week-28 findings from a phototherapy substudy, where Rinvoq combined with NB-UVB phototherapy showed higher repigmentation responses than Rinvoq alone. Rinvoq is approved in the EU for NSV treatment and is under FDA review in the US.

AbbVie's risankizumab (Skyrizi) showed higher clinical remission and endoscopic response rates at week 12 and 24 in Crohn's disease patients compared to placebo, per a phase 3 AFFIRM study. The drug demonstrated a similar safety profile to other indications, according to a presentation at the ACG Annual Scientific Meeting. The study enrolled 289 adults with moderate to severe Crohn's disease, with primary endpoints being clinical remission and endoscopic response at week 12.

AbbVie's stock rose 3.1% to $284.58 after positive Phase 3 trial data for Skyrizi in treating Crohn's disease was released. The data is seen as a validation of AbbVie's immunology strategy, which is key to its growth post-Humira.

AbbVie Inc. (ABBV) shares rose 3.1% after positive Phase 3 data for subcutaneous SKYRIZI in Crohn’s disease and supportive analyst price-target updates. The company also shared additional SKYRIZI and RINVOQ data in inflammatory bowel disease. Analysts have maintained positive ratings, with some raising price targets in early October. The gain occurred despite an October 5 filing updating 2026 earnings guidance to reflect an acquired IPR&D and milestones expense.

AbbVie (ABBV) presented Phase 3 AFFIRM trial data at the American College of Gastroenterology 2026 Annual Scientific Meeting, showing subcutaneous Skyrizi achieved 35.8% endoscopic remission in Crohn's patients at Week 24, compared to 9.1% for placebo. The drug is under regulatory review. ABBV closed at $274.36, down 2.40%.

AbbVie reported Phase 3 AFFIRM data showing subcutaneous Skyrizi achieved 35.8% endoscopic remission in Crohn's patients at Week 24, surpassing placebo. The trial involved 289 adults, with co-primary endpoints met at Week 12. Results were presented at a gastroenterology conference. ABBV stock closed at $274.36, down 2.40%.